Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$44.74M+398.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Goff
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 540
- Beta
- 0.60
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 12.39
Financials
Revenue
$44.74M+398.0%Net Income
$-100.70MEBITDA
$-109.20MFree Cash Flow
$-58.52MEPS (diluted)
$-1.69Shares Outstanding (diluted)
59.49M+54.3%Operating Expenses
$152.30MCash & Debt
$617.58MReturn of Capital
$0.00Revenue by Segment (annual)
$54.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.03M | $-412.78M | $-7.12 |
| 2024 | $36.50M | $673.73M | $11.86 |
| 2023 | $26.82M | $-352.09M | $-6.33 |
| 2022 | $14.24M | $-231.80M | $-4.23 |
| 2021 | $0.00 | $1.60B | $-6.36 |
| 2020 | $0.00 | $-327.37M | $-4.74 |
| 2019 | $117.91M | $-411.47M | $-6.61 |
| 2018 | $94.39M | $-346.03M | $-6.03 |
| 2017 | $43.01M | $-314.67M | $-6.75 |
| 2016 | $69.89M | $-198.47M | $-5.07 |
| 2015 | $59.12M | $-117.73M | $-3.15 |
| 2014 | $65.36M | $-53.50M | $-1.59 |
| 2013 | $25.55M | $-39.41M | $-2.56 |
| 2012 | $25.11M | $-20.10M | $-0.86 |
Valuation
AGIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130Social Signal Score
Mentions (1)
- Newszacks.com·3d ago·Positive
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $-1.21 per share
Typical surprise +6.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-1.69 vs $-1.65miss
- Wed, Apr 29$-1.69 vs $-1.81beat
- Thu, Feb 12$-1.85 vs $-1.97beat
- Thu, Oct 30$-1.78 vs $-1.93beat
- Thu, Jul 31$-1.93 vs $-1.74miss
- Thu, May 1$-1.55 vs $-1.80beat
Estimates and results for AGIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AGIO officers and directors.
- Bought
- —
- Sold
- $3.1m
0 trades
17 trades
- Gheuens Sarahsold
- Gheuens Sarahsold
- Burns James Williamsold
- Gheuens Sarahsold
- Jones Ceciliasold
- Milanova Tsvetasold
- Viswanadhan Krishnansold
- Goff Briansold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (14d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (22d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.